cyrilzakka/clinical-trials huggingface dataset:
The Effect of Buckwheat and Couscous on Satiety and Food Intake in Young Adults

A diet rich in whole grains has been linked to multiple beneficial health outcomes, including cardiovascular health, weight loss and a decreased risk of acquiring type 2 diabetes. However, grain products vary due to their botanical origin, composition, and post-harvest processing. While wheat is considered a dominant grain crop in Canada, the minor crops, including gluten-free buckwheat, become popular alternatives to wheat products such as couscous. Both buckwheat groats and couscous are traditionally consumed in the form of the porridge or side dish, however, their acute effects on satiety and food intake remain unknown. The objective of this study is to investigate the short-term effects of couscous and buckwheat on satiety and short-term food intake in young adult males.


Eligibility Criteria:
Inclusion Criteria:

* Healthy
* 18-30 years

Exclusion Criteria:

* Smokers
* Taking medication
* Breakfast skippers
Normoxic Challenges Utility to Evaluate Blood Loss

This study will evaluate the impact of repeated normoxic challenges on cerebral oxygenation as a measure of the effect of blood loss on DO2 during surgical procedures.


Eligibility Criteria:
Inclusion Criteria:

* Elective surgery
* High risk of intraoperative blood loss
* General anaesthesia

Exclusion Criteria:

* Respiratory insufficiency
* Ischemic heart disease
* Stroke
* ASA classification \> 3
* Laparoscopic surgery
A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients

The purpose of this study is to evaluate technetium-99m (99mTc) pertechnetate produced by a cyclotron as a replacement for 99mTc pertechnetate obtained from a generator containing the parent isotope Molybdenum-99 (99Mo). 99mTc pertechnetate is currently used in nuclear medicine departments across the country. 99Mo is produced by a number of ageing nuclear reactors across the world and severe shortages of the isotope have occurred in the past few years. Cyclotron-produced 99mTc offers an alternative decentralized production method on a regional basis. Since the manufacturing process is different, the safety and efficacy of cyclotron-produced 99mTc pertechnetate must be evaluated in human subjects to enable its routine clinical use.


Eligibility Criteria:
Inclusion Criteria:

* WHO performance status 0-2
* Older than the age of majority in the province where the study is performed, and be able to consent to the project
* Ambulatory and able to lie supine for the duration of the examination.
* Able and willing to return for a subsequent visit within 7 days to undergo a repeat examination and participate in a follow-up phone call to monitor for adverse events.

Subject referred for nuclear medicine examination for one of the following indications:

* Biochemically documented hyperthyroidism, referred for scintigraphy to evaluate the differential diagnosis of hyperthyroidism or to plan radioiodine treatment.
* Referred for bone scintigraphy for the evaluation of metastases, fractures, or inflammatory conditions. Subjects referred for a limited area (localized) bone scan are eligible, provided they agree to undergo a whole-body scan as part of the procedure.

Exclusion Criteria:

* Pregnant, planning to become pregnant within 30 days
* Severe evolving health problems (unstable coronary disease, liver failure, heart failure, end-stage-renal failure, hospitalized subjects with severe medical conditions) that may confound the assessment of adverse events.

For subjects evaluated for hyperthyroidism:

* Recent iodine-containing IV contrast administration (\< 6 weeks)
* Recent amiodarone usage (\< 8 weeks)

For subjects evaluated for bone scintigraphy:

• Recent trauma occurring less than 24 hours prior to the first 99mTc bone scintigraphy examination, or between the first and second 99mTc bone scintigraphy examination.

Women who are breast-feeding are eligible to participate in this study, but must cease breast-feeding for 24 hours following the 99mTc examinations. They can draw their milk and discard it during this period, and use either formula or previously collected milk to feed their child.
Hypofractionated Whole Pelvic Radiotherapy of the Prostate

This is a phase I feasibility study to evaluate the feasibility of hypofractionated whole pelvis radiotherapy in 35 patients with biopsy-proven intermediate- to high-risk prostate cancer as defined by NCCN risk criteria. Patients will have \>15% risk of lymph node involvement as defined by the Roach equation 2/3(PSA)+10(Gleason Score-6). Day 0 of the study will be defined as the time of first LHRH/agonist/antagonist injection of hormone therapy. Radiation therapy should begin within 8 weeks (+/- 1 week) after the date of the first LHRH agonist/antagonist injection. Patients will be followed at 6 weeks and then every 3 months for the first 24 months after completion of radiotherapy in a similar schedule to usual standard of care. A history and physical, PSA, testosterone and EPIC-26 questionnaire will be collected at each visit. Any toxicity according to CTCAE v. 4.0 criteria will be documented. An interim analysis for evaluating acute toxicity (≤90 days) will be performed after the first follow-up visit of the20th patient enrolled on protocol. The trial will be terminated if \>30% acute grade 2 or \>5% grade 3 or greater toxicity is observed as a result of radiation treatment by CTCAE v. 4.0 criteria. Grade 2 toxicity is defined as a minimal, local or noninvasive intervention. Grade 3 toxicity is defined as a severe or medically significant but not immediately life-threatening event requiring hospitalization or prolongation of hospitalization. Previous studies have demonstrated approximately 30% and 5% incidence of Grade 2 and Grade 3 or greater toxicity, respectively, with conventionally fractionated radiotherapy followed by brachytherapy.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed intermediate- to high-risk prostate adenocarcinoma (T1c-T3b, PSA \>10, and/or Gleason score ≥ 7) who have a greater than 15% risk of lymph node involvement as determined by the Roach equation.
* History/physical examination with digital rectal examination of the prostate within 8 weeks prior to registration
* Zubrod performance status 0-2
* Age ≥18 years
* Ability to understand a written informed consent document, and the willingness to sign it

Exclusion Criteria:

* Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5 years.
* Evidence of distant metastases
* Regional lymph node involvement
* Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
* Previous pelvic irradiation, prostate brachytherapy
* Previous or concurrent cytotoxic chemotherapy for prostate cancer
* Patients with history of inflammatory bowel disease or major bowel surgery.
* Prior transurethral resection of the prostate (TURP) procedure.
Study of the Reduction of the Prescriptions of Benzodiazepines and Related

The significant consumption of Benzodiazepines and related drugs in the elderly outside of good practice recommendations is a major issue in the care of the elderly. Adverse effects have been the subject of numerous studies, leading to falls, addictions and even deaths. The general practitioner is often faced with long-term medication intake which is not consistent with a good benefit/risk balance, but stopping or reducing the dosage remains a problem in current practice.

The Aftercare and Geriatric Rehabilitation services due to their operation (several weeks of hospitalization) seek to adapt the patient's therapies in order to obtain the most convincing benefit/risk balance possible. A reduction or withdrawal of treatments with Benzodiazepines or related drugs are therefore frequently initiated.

The aim of this research is to quantify among the patients who benefited from a dosage reduction of Benzodiazepines and related drugs during a stay in the Geriatric Care and Aftercare and Rehabilitation department, the number of patients who had an increase of this treatment within 12 weeks following discharge from hospitalization.

Eligibility Criteria:
Inclusion Criteria:

* Major subject (≥ 75 years old)
* Subject discharged from a geriatric Follow-up Care and Rehabilitation service for whom a reduction in the dosage of Benzodiazepines and related drugs was carried out during hospitalization and who returned home (individual or EHPAD) after hospitalization.
* Subject not opposing, after information, the reuse of their data for the purposes of this research.

Exclusion Criteria:

* Subject having expressed opposition to participating in the study.
* Subject having treatment with Benzodiazepine to prevent recurrence of epileptic seizures.
Physiological Mechanisms of Therapeutic Horseback Riding Intervention Effects in a Psychiatric Population of ASD Youth

This randomized control trial (RCT) seeks to assess the mechanisms underlying Therapeutic Horseback Riding's (THR) previously observed significant positive effects on ASD youth, particularly those with co-occurring psychiatric disorders, and to refine information on the durability, dose and sub-population effects of the intervention.

This randomized control trial (RCT) will test the hypothesis that physiological response patterns of salivary cortisol, cardiovascular, and electrodermal activity account for our previously observed significant outcomes (i.e., reduced irritability and hyperactivity, and improved social and communication), and additional outcomes (emotion regulation caregiver quality of life and crisis mental health care usage), in youth ages 6-16 yrs. with ASD and co-occurring psychiatric diagnoses randomized to a 10-week manualized THR intervention compared to a no-horse Barn Activity (BA) control (Aim 1). We will evaluate the durability of Aim 1 outcomes in the THR group compared to the BA control group six-months after the intervention period (Aim 2). Finally, we will explore dose and sub-population effects of THR and BA interventions by comparing effect size differences in THR and BA groups to (a) a 10-week wait-list control group; (b) a Hybrid intervention group (five weeks BA followed by five weeks THR); and (c) a subsample of the THR study population randomized following psychiatric hospitalization (Aim 3).

Eligibility Criteria:
Inclusion Criteria:

* documented ASD diagnosis and a co-occurring psychiatric disorder
* ABC Irritability subscale score ≥8
* Leiter-III Nonverbal IQ ≥ 40
* meet Symptom Criterion score (minimum number of symptoms necessary for a DSM-V (mood, anxiety, or ADHD diagnosis) on CASI-5)
* meet ASD cut-offs on the SCQ (≥ 11) and on ADOS-2
* Only one child with ASD per family to maintain independent observations
* a consistent caregiver (i.e., parent or legal guardian) to complete study outcome measures

Exclusion Criteria:

* medical or behavioral issues that prevent participation
* ward of the state
* judged during riding center screen to have significant riding experience
* smoking or regular use of oral, inhaled, or topical steroids on a regular basis, factors known to affect cortisol levels
* Participants weighing 200 pounds or greater will be excluded due to the riding center's safety policies
* Participants will not be allowed to begin baseline assessments until at least six months have passed from the time they last engaged in mounted EAAT, given pilot evidence for the six-month maintenance of THR effects.
Non-Interventional (Observational) Post-Authorization Safety Study of HES 130/0.42 in Paediatric Patients

This observational (non-interventional) post-authorization safety study (PASS) will investigate the application of Venofundin 6% and of Tetraspan 6% in children with special regard to drug safety.


Eligibility Criteria:
Inclusion Criteria:

* Age ≤12 years
* Risk of anaesthesia: American Society of Anaesthesiologists (ASA) risk score: I - III
* infusion of Venofundin 6% or of Tetraspan 6%
* elective intervention

Exclusion Criteria:

* contraindications according to SmPC
Neurocircuitry of Obsessive-Compulsive Disorder: Modulation by Transcranial Magnetic Stimulation

The purpose of this study is to test the effects of non-invasive neuromodulation, transcranial magnetic stimulation on brain function in individuals with obsessive-compulsive disorder (OCD). This study is focused on the mechanism(s) by which brain stimulation might change the functioning of regions implicated in OCD, and thereby inform possible future therapeutic uses.


Eligibility Criteria:
Inclusion Criteria:

* Current primary OCD diagnosis and current Y-BOCS total score of ≥16
* 18-70 years of age
* Ability to speak, read, write, and understand English sufficiently well to complete study procedures and provide informed consent
* No use of psychiatric medications or stable psychiatric medication use for a minimum of 6 week prior to study entry
* Ongoing psychotherapy allowed if already established for three months or more before study entry

Exclusion Criteria:

* History of primary psychotic disorder or bipolar disorder
* Present acute suicidality
* History of head injury, epilepsy, or other clinically significant neurological illness except tic disorders
* Active systemic medical (metabolic, endocrine, chronic inflammatory, vascular, autoimmune) disease
* Premorbid intelligence quotient (IQ) estimate \< 80
* Visual disturbance (\<20/40 Snellen visual acuity, corrected)
* Current, or alcohol or illicit substance abuse/dependence in the last 3 months
* Contraindications to TMS or MRI: metallic foreign objects, e.g., aneurysm clips/pacemakers, or questionable history of metal fragments, claustrophobia
* Women who are pregnant or breastfeeding. All women participants of reproductive age are required to have a negative pregnancy test prior to enrollment and use medically acceptable birth control throughout the study (barrier and/or oral contraceptives)
* Current psychotic symptoms
* An increased risk of seizure, determined by history
* Medications judged to notably affect cortical excitability e.g., anticonvulsants or high-dose benzodiazepines (\> 4 mg/day of clonazepam or equivalent)
* Predominant hoarding symptoms
Patient Experience Data in Radiation Oncology

The project is part of the overarching goal of improving patient-centric radiation oncology. This pilot project aims to develop an instrument that can be used to collect clinically relevant patient-reported outcome data on adverse effects during and after RT. This real-world evidence (RWE) database will be the basis to monitor and evaluate future technological developments, combination treatments (e.g. radioimmunotherapy, etc.), or changes in treatment protocols. The pseudonymized data will be linked to data in the oncological information system and dosimetric data from the treatment planning system. In this way, they represent a basic building block of patient-oriented development of clinical radiotherapy.


Eligibility Criteria:
Inclusion Criteria:

* all patients receiving external beam radiotherapy

Exclusion Criteria:

* unable to independently answer questionnaires on radiation-induced side effects
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.


Eligibility Criteria:
Inclusion Criteria:

* No known history of neurological disease, or meet criteria for one of the following: Corticobasal Syndrome or Degeneration (CBS or CBD); Progressive Supranuclear Palsy (PSP); or Oligo- or Variant- Progressive Supranuclear Palsy (o/vPSP)
* Needs a reliable study partner who has frequent contact with the participant, who is available to provide information about the participant, and who can accompany the participant to research visits as needed
* Must be willing and able to undergo testing procedures, which include longitudinal follow-up visits
* Must be able to walk five steps with minimal assistance

Exclusion Criteria:

* Significant neurological disease other than CBD, PSP, or a variant PSP syndrome.
* Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or metal fragments or metal objects in the eyes, skin, or body
* In the site investigator's opinion, inability to complete sufficient key study procedures, or some other equivalent assessment of impairment
Evaluation of Clinical Decision Support in Opioid Tapering

The 2022 Center for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends that when tapering a patient's opioid dose, doses should be decreased at a slow rate to reduce the risk of withdrawal symptoms, overdose, and to promote tolerance of the tapering. This project will evaluate a clinical decision support (CDS) tool in the form of a clinical care pathway that gives providers information, recommendations, and educational material on strategies for opioid tapering. Primary care providers will be randomized at the clinic location to a control arm or intervention arm. The control arm will have the clinical care pathway available, but will not be reminded of the pathway when tapering a patient. The intervention arm will receive a nudge when prescribing a tapering opioid strategy to a patient to use the clinical care pathway. The rate of opioid tapering in line with CDC guidelines will be examined as well as long-term patient outcomes of opioid overdose or poisoning using existing patient health records. The study period will be approximately 18 months.


Eligibility Criteria:
Inclusion Criteria: Primary care patients being tapered from an opioid. Tapering patients:

* Have an active opioid prescription for more than 3 months and
* Prescribed more than 90 morphine milligram equivalents (MME) per day or
* Co-prescribed an opioid and benzodiazepine or
* Received a reduction in opioid dosage by more than 5% MME per day

Exclusion Criteria:

* Patients \<12 and \>89
* Patients with active cancer diagnosis in last 1 year
* Patients with hospice care/palliative care order
* Patients with sickle cell disease diagnosis
Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation

To investigate the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation. Patients are enrolled into two groups according to the downstaging therapy they undergo before transplantion.


Eligibility Criteria:
(1) age ≥18 years; (2) exceeding UCSF criteria; (3) absence of vascular invasion, nodal involvement, or extrahepatic metastases; (4) receiving TACE treatment or LTFVD treatment for downstaging purposes.
Effects of NIV and CPAP on Ventilation Distribution, Measured by EIT, During Deep Sedation in Paediatric Patients

In patients undergoing spontaneous breathing (SB) deep sedation there is a re-distribution of ventilation towards lungs non-dependant areas (ventral areas in supine position).

Non-invasive ventilation (NIV), offering positive pressure, should favour a better ventilation of dependant areas (dorsal areas in supine position), making ventilation more homogeneous and increasing functional residual capacity.

Electrical impedance tomography (EIT) is a non-invasive, non-operator dependent, bedside, radiations-free diagnostic tool, feasible in paediatric patients and repeatable; it allows to study ventilation distribution, and it can measure and calculate also parameters that are related to the homogeneity of ventilation and the response to certain therapeutic maneuvers, such as anaesthesia or PEEP-application.

Uses of EIT in paediatric age are described in literature, but it has never been described as being used in Non-Operating Room Anaesthesia, nor in other cases of SB deep sedation. In addition, the impact of NIV on the distribution of ventilation in healthy paediatric patients undergoing deep sedation has never been described.


Eligibility Criteria:
Inclusion Criteria:

* Paediatric age (from 1 to 10 years old)
* ASA score ≤ 2
* Sedation time ≥ 30 min

Exclusion Criteria:

* ASA score ≥ 3
* Lung pathologies (such as asthma, bronchopulmonary dysplasia, obstructive sleep apnoea) Preterm infant
* Severe obesity
* Dorso-lumbar pathologies or other bone pathologies associated with restrictive lung disease (such as scoliosis, kyphosis)
* Neuromuscular, mitochondrial, metabolic or chromosomal disease with hypotonia
* CPAP or NIV treatment at home
* Hand-Bag Ventilation (HBV) during the procedure (loss of the respiratory drive)
* Non-Total IntraVenous Anaesthesia (TIVA), adherence to the sedation protocol
* Implantable devices not compatible with EIT (such as pace-makers and implantable cardioverter defibrillator)
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease

The purpose of the research study is to determine if rasagiline is an effective treatment for fatigue in patients with Parkinson's disease (PD).

Despite the fact that fatigue affects 40-50% of all patients with PD and is a leading cause of disability, we currently do not have any effective treatments for this symptom. Rasagiline is a well-tolerated and effective treatment for the motor symptoms of PD. Rasagiline is a MAO-B inhibitor that may decrease the breakdown of dopamine. Many patients report an improvement in their energy levels when on this medication. A proven treatment for PD fatigue would significantly improve the quality of life for numerous patients and their caregivers.

Eligibility Criteria:
Inclusion Criteria:

1. A clinical diagnosis of idiopathic PD by a movement disorders specialist. All subjects will be diagnosed using the UK Brain Bank criteria (Hughes et al., 1992).
2. Age between 40-85 years.
3. Able to sign and understand informed consent; and cognitively able to carry out the procedures in the study
4. Stable on all PD medications for at least 30 days; and psychotropic medications for at least 90 days.
5. Treatment naïve subjects who are appropriate candidates to begin MAO-inhibitor monotherapy as treatment for their PD may also be included in this study.
6. Fatigue Severity Scale ≥ 36 (KRupps et al., 1989)

Exclusion Criteria:

1. Clinically significant medical disease that is associated independently with fatigue (e.g. significant cardiac or pulmonary disease, anemia, obstructive sleep apnea, liver or kidney failure).
2. History of neurological illnesses other than PD or a history of a significant head trauma (involving unconsciousness).
3. Evidence of secondary or atypical parkinsonism as suggested by the presence of any of the following: 1) history of stroke(s), 2) exposure to toxins or neuroleptics, 3) history of encephalitis, 4) neurological signs of upper motor neuron disease, cerebellar involvement, supranuclear gaze palsy, or significant orthostatic hypotension.
4. MRI or CT scan with significant evidence of brain atrophy or other abnormalities (e.g. lacunar infarcts or iron deposits in the putamen.
5. Clinical diagnoses of dementia; or an MMSE score of \< 25.
6. Unstable, newly diagnosed, or newly treated (i.e. less than 3 months) major psychiatric disorder such as depression or anxiety
7. Beck's Depression Inventory score \>14.
8. Current or prior placement of Deep Brain Stimulator.
9. Currently taking an MAO-B inhibitor or medications which are used as fatigue treatments, including amantadine, modafinil, methylphenidate, atomoxetine or other psychostimulants.
10. Previously taken an MAO-B inhibitor for more than 2 weeks.
11. Hypersensitivity to rasagiline or its products
12. On mirtazapine, venlafaxine, regular use of compounds with vasoconstrictors, tramadol, meperidine, propoxyphene, dextromethorphan, St. John's wort, cyclobenzaprine
13. On omeprazole, ciprofloxacin or drugs that are metabolized through CYP1A2